Foghorn Therapeutics Files 8-K: Material Agreement & Other Events
Ticker: FHTX · Form: 8-K · Filed: May 22, 2024 · CIK: 1822462
| Field | Detail |
|---|---|
| Company | Foghorn Therapeutics Inc. (FHTX) |
| Form Type | 8-K |
| Filed Date | May 22, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $5.51, $5.5099 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing, corporate-event
TL;DR
Foghorn Therapeutics signed a big deal, filed an 8-K. Details inside.
AI Summary
On May 20, 2024, Foghorn Therapeutics Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits as part of this 8-K filing.
Why It Matters
This filing indicates a significant new agreement for Foghorn Therapeutics, which could impact its strategic direction and financial future.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, requiring further analysis of the agreement's terms.
Key Players & Entities
- Foghorn Therapeutics Inc. (company) — Registrant
- May 20, 2024 (date) — Date of earliest event reported
- 001-39634 (company) — Commission File Number
- 500 Technology Square, Ste 700, Cambridge, MA 02139 (location) — Address of principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Foghorn Therapeutics?
The filing states that Foghorn Therapeutics Inc. entered into a material definitive agreement on May 20, 2024, but the specific details of this agreement are not provided in the provided text.
What other items are reported in this 8-K filing?
In addition to the material definitive agreement, the filing also reports 'Other Events' and 'Financial Statements and Exhibits'.
When was this 8-K report filed?
This 8-K report was filed on May 22, 2024.
What is Foghorn Therapeutics Inc.'s state of incorporation and fiscal year end?
Foghorn Therapeutics Inc. is incorporated in Delaware and its fiscal year ends on December 31.
What is the primary business of Foghorn Therapeutics Inc. according to its SIC code?
According to its Standard Industrial Classification (SIC) code [2834], Foghorn Therapeutics Inc. is involved in Pharmaceutical Preparations.
Filing Stats: 999 words · 4 min read · ~3 pages · Grade level 11.8 · Accepted 2024-05-22 16:05:03
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share FHTX The Nasdaq
- $5.51 — Stock"), at a public offering price of $5.51 per share and, to certain investors in
- $5.5099 — mon stock at a public offering price of $5.5099 (the "Pre-Funded Warrants") per Pre-Fun
Filing Documents
- d822638d8k.htm (8-K) — 30KB
- d822638dex11.htm (EX-1.1) — 218KB
- d822638dex41.htm (EX-4.1) — 68KB
- d822638dex51.htm (EX-5.1) — 7KB
- g822638g0522065903866.jpg (GRAPHIC) — 2KB
- 0001193125-24-144934.txt ( ) — 535KB
- fhtx-20240520.xsd (EX-101.SCH) — 3KB
- fhtx-20240520_lab.xml (EX-101.LAB) — 18KB
- fhtx-20240520_pre.xml (EX-101.PRE) — 11KB
- d822638d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit 1.1 Underwriting Agreement dated May 20, 2024, by and among Foghorn Therapeutics Inc. and Jefferies LLC, TD Securities (USA) LLC and Evercore Group L.L.C, as representatives of the several underwriters named in Schedule 1 thereto 4.1 Form of Pre-Funded Warrant 5.1 Opinion of Ropes & Gray LLP 23.1 Consent of Ropes & Gray LLP (included in the opinion filed as Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FOGHORN THERAPEUTICS INC. Date: May 22, 2024 /s/ Kristian Humer Kristian Humer Chief Financial Officer